These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35742822)

  • 1. Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers.
    Borrelli S; Matarazzo I; Lembo E; Peccarino L; Annoiato C; Scognamiglio MR; Foderini A; Ruotolo C; Franculli A; Capozzi F; Yavorskiy P; Merheb F; Provenzano M; La Manna G; De Nicola L; Minutolo R; Garofalo C
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].
    De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patiromer: A Review in Hyperkalaemia.
    Blair HA
    Clin Drug Investig; 2018 Aug; 38(8):785-794. PubMed ID: 30030701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.
    Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M
    Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet.
    Clegg DJ; Headley SA; Germain MJ
    Kidney Med; 2020; 2(4):476-487. PubMed ID: 32775988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension.
    Kovesdy CP; Appel LJ; Grams ME; Gutekunst L; McCullough PA; Palmer BF; Pitt B; Sica DA; Townsend RR
    Am J Kidney Dis; 2017 Dec; 70(6):844-858. PubMed ID: 29029808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical patient care appraisals with use of new potassium binders in heart failure and chronic kidney diseases.
    Senni M; Sciatti E; Bussalino E; D'Elia E; Ravera M; Paoletti E
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):781-789. PubMed ID: 37695628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension.
    Kovesdy CP; Appel LJ; Grams ME; Gutekunst L; McCullough PA; Palmer BF; Pitt B; Sica DA; Townsend RR
    J Am Soc Hypertens; 2017 Dec; 11(12):783-800. PubMed ID: 29030153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
    Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
    Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.
    Rossignol P; Silva-Cardoso J; Kosiborod MN; Brandenburg V; Cleland JG; Hadimeri H; Hullin R; Makela S; Mörtl D; Paoletti E; Pollock C; Vogt L; Jadoul M; Butler J
    Pharmacol Res; 2022 Aug; 182():106277. PubMed ID: 35662631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies.
    Valdivielso JM; Balafa O; Ekart R; Ferro CJ; Mallamaci F; Mark PB; Rossignol P; Sarafidis P; Del Vecchio L; Ortiz A
    Drugs; 2021 Sep; 81(13):1467-1489. PubMed ID: 34313978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.